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Abstract
Background: Heart failure (HF) patients with diabetes (DM) have an adverse prognosis and reduced functional
capacity, which could be associated with cardiac fibrosis, increased chamber stiffness and reduced left ventricular
(LV) contractile reserve. Galectin-3 (Gal-3) and fibulin-1 are circulating biomarkers potentially reflecting cardiac
fibrosis. We hypothesize that plasma levels of Gal-3 and fibulin-1 are elevated in HF patients with DM and are
associated with reduced LV contractile reserve in these patients.
Methods: A total of 155 patients with HF with reduced ejection fraction underwent a low-dose dobutamine
echocardiography and blood sampling for biomarker measurements. Patients were classified according to history of
DM and an oral glucose tolerance test (OGTT) as: normal glucose tolerance (NGT) (n = 70), impaired glucose
tolerance (IGT) (n = 25) and DM (n = 60).
Results: Galectin-3 levels were elevated in DM patients as compared to non-diabetic patients (P = 0.02), while
higher fibulin-1 levels were observed in HF patients with IGF and DM (P = 0.07). Reduced LV contractile reserve was
associated with increasing Gal-3 levels (β = −0.19, P = 0.03) although, this association was attenuated after adjustment
for estimated glomerular filtration rate (P = 0.66). Fibulin-1 was not associated with LV contractile reserve (P = 0.71).
Conclusions: Galectin-3 and fibulin-1 levels were elevated in HF patients with impaired glucose metabolism. However,
reduced LV contractile reserve among HF patients with DM does not to have an independent impact on plasma Gal-3
and fibulin-1 levels.
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Background
Patients with heart failure with reduced ejection fraction
(HFrEF) and concomitant diabetes (DM) have a consid-
erably increased mortality rate and reduced exercise cap-
acity compared to non-diabetic HFrEF patients [1]. It is
well-established that in HFrEF DM is frequent, and
screening with an oral glucose tolerance test (OGTT) re-
veals a prevalence of more than 30% [2]. We have previ-
ously reported that the co-existence of DM, whether it is
by history or newly diagnosed is associated with a
reduced left ventricular (LV) contractile reserve assessed
by low-dose dobutamine echocardiography (LDDE)
among HFrEF patients [3]. Further, reduced LV contract-
ile reserve is predictive of prognosis and thus could con-
tribute to the unfavorable outcome of diabetic HFrEF
patients [4]. The pathophysiological processes leading to
reduced LV contractile reserve remain to be fully eluci-
dated but have been associated with myocardial fibrosis
in patients with cardiomyopathy [5].
Galectin-3 (Gal-3) is a galactoside-binding protein
which is released to the circulation by activated macro-
phages and is considered a biomarker of cardiac fibrosis
and remodeling [6]. In the myocardium, Gal-3 is primarily
expressed in the fibroblasts and in macrophages and plays
an important role in the formation of myocardial fibrosis
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through activation of fibroblasts [6]. In DM increased
plasma Gal-3 levels have been associated with both
macro- and microvascular complications [7]. Moreover,
high levels of Gal-3 are reported in patients with chronic
HFrEF and renal dysfunction [8]. Hence, we hypothesize
that elevated Gal-3 is associated with reduced LV contract-
ile reserve found among HFrEF patients with DM.
The novel promising biomarker fibulin-1 is emerging
as a potential biomarker of cardiomyopathy [9]. Fibulin-
1 is an extracellular matrix glycoprotein and is consid-
ered to reflect pathological accumulation of extracellular
matrix components surrounding vascular smooth muscle
cells [10]. To our knowledge no previous studies of
fibulin-1 in HFrEF patients have been performed. In pa-
tients with chronic renal dysfunction high levels of
fibulin-1 are associated with increasing age, HbA1c and
creatinine [11]. Plasma fibulin-1 levels have been investi-
gated in patients with aortic stenosis, where an association
with decreased longitudinal systolic LV function has been
observed [12]. The effects of HFrEF and abnormal glucose
metabolism on circulating fibulin-1 levels have, to our
knowledge, not been examined previously.
Therefore, the aims of this study were to evaluate the
impact of DM and abnormal glucose metabolism on
plasma Gal-3 and fibulin-1 concentrations, and further
to investigate whether Gal-3 and fibulin-1 levels were as-
sociated with LV contractile reserve in HFrEF patients
according to presence of DM.
Methods
Study population
Between May 2008 and June 2010 155 patients were re-
cruited from the HF clinic at Frederiksberg University
Hospital, Copenhagen, Denmark. The cohort has pre-
viously been described in detail [3]. Patients were en-
rolled in the present study if LV ejection fraction
(LVEF) was ≤ 45% by echocardiography and baseline
measurements of Gal-3 and fibulin-1 were available.
Patients were classified as having DM either by history
or DM newly diagnosed by an oral glucose tolerance test
(OGTT). The OGTT was performed in patients without
known DM within 2 weeks after the baseline visit by in-
gestion of 75 g glucose dissolved in 250 mL water. Plasma
glucose was measured in the fasting state (fasting plasma
glucose, FPG) and after 2 h (2hPG). Glycemic status was
defined according to WHO diagnostic criteria: Normal
glucose tolerance (NGT): FPG <6.1 mmol/L and 2hPG
<7.8 mmol/L. Impaired glucose tolerance (IGT): FPG
<7.0 mmol/L and 2hPG between 7.8 and 11.1 mmol/L.
DM: FPG >7.0 mmol/L and/or 2hPG >11.1 mmol/L.
Echocardiography
Resting echocardiography and LDDE (as described in
detail previously [3]) was performed within 2 weeks after
referral to the outpatient clinic on a standard ultrasound
machine (IE-33, Philips Inc.) and stored for later analysis
[3]. The Doppler analyses were based on an average of
five beats for patients with sinus rhythm and 10 beats
for patients with atrial fibrillation (AF). LVEF was calcu-
lated by the biplane method from apical four- and two-
chamber views [13].
Laboratory analysis
After a minimum 8-h overnight fast and 20 min of su-
pine rest, venous blood was obtained for measurement.
Blood was drawn into EDTA tubes, promptly centri-
fuged at 4 °C, and plasma was frozen at −80 °C in ali-
quots until laboratory analyses were performed. Insulin
resistance was estimated using the Homeostasis Model
of Assessment-Insulin Resistance (HOMA-IR): Fasting
Glucose (mmol/L) x Insulin (mU/L)/22.5. Galectin-3
was determined using an ELISA kit (BG Medicine,
Waltham, USA) [14]. The lower detection limit was
1.32 ng/mL, intra- and interassay coefficient of variation
(CV) <6% and <10%, respectively [14]. The fibulin-1
double-antibody sandwich ELISA has previously been
described extensively [15]. Antibodies are a mouse anti-
fibulin monoclonal 5D12/H7 IgG and goat anti-rabbit
IgG alkaline phosphatase [16]. The assay has a lower
detection limit of 1.56 μg/mL, an intra- and interassay
CV <8% and ~10%, respectively [15].
Statistical analysis
Distribution of the biomarkers Gal-3 and fibulin-1 in the
total study population is depicted in histograms. Con-
tinuous variables are presented as mean (SD) or as me-
dian (interquartile range), as appropriate. The groups
were compared using independent sample T-test or
Kruskall-Wallis’ test if the assumption of Gaussian dis-
tribution was not met. Fibulin-1 levels were normally
distributed, while GAL-3 levels were not. The IGT group
was small, and we previously demonstrated that LV con-
tractile reserve is reduced in patients with known or
new DM but not affected by IGT. Hence, we divided the
population in two groups: DM (new or known), and
non-DM (NGT or IGT) in the multivariable linear re-
gression analysis. The associations between Gal-3,
fibulin-1 and HbA1c were depicted in scatter plots. Mul-
tivariable linear regression analyses examining the asso-
ciation between Gal-3 and fibulin-1 levels with LV
function were performed. The multivariable regression
analyses included co-variables considered of having po-
tential impact of LV contractile reserve in univariable
analysis: Age, sex, presence of ischemic heart disease
(IHD), estimated glomerular filtration rate (eGFR), atrial
fibrillation (AF) and DM status [3]. Further, the relation-
ship between Gal-3, fibulin-1 and parameters of glucose
metabolism as HbA1c and DM were examined in
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multivariable models including confounders associated
with Gal-3 and fibulin-1 at the P <0.1 level in univariable
analysis. Multivariable linear regression analysis was per-
formed as stepwise analyses with backward elimination.
Logarithmic transformation of Gal-3 and fibulin-1 were
used in the linear regression analyses to meet the as-
sumptions of linearity. Statistical analyses were per-
formed using the SPSS 22 package.
Results
According to the OGTT and history of DM, 70 (45%) of
the HF patients had NGT, 25 (16%) had IGT, and 60
(39%) DM, of these 28 (18%) were newly diagnosed.
Baseline characteristics according to DM status are pre-
sented in Table 1. There were no significant differences
with regard to age, gender distribution, eGFR, and IHD
between HF patients with and without DM. LVEF at rest
(P = 0.003), LV contractile reserve (P = 0.01), and systolic
longitudinal tissue velocity (S’) during LDDE (P = 0.03)
were reduced among patients with DM compared to the
non-diabetic patients. Distributions of Gal-3 and of fibu-
lin-1 are displayed in Fig. 1. Median (IQR) Gal-3 was
16.0 (12.8–21.0) ng/mL, and mean fibulin-1 was 57 ±
16 μg/mL. The univariable associations between the
biomarkers and clinical parameters are shown in
Table 2. Galectin-3 levels were strongly associated
with impaired renal function (eGFR) (β = −0.49, P < 0.001)
and (β = −0.46, P < 0.001) after full adjustment. Fibulin-1
levels were correlated to eGFR, NT-proBNP, presence of
AF, and age (Table 2) and remained correlated to
eGFR (β = −0.26, P < 0.001) after full adjustment.
Galectin-3, fibulin-1 and relationship with glucose
metabolism
Plasma Gal-3 levels were elevated among HF patients
with DM (17.9 (12.9 26.1) ng/mL) and IGT (16.8 (14.1–
22.1) ng/mL) as compared with NGT patients 15.2
(11.6–18.3) ng/mL (P = 0.02) (Table 1). No difference
was found in patients classified as IGT compared to
NGT (P = 0.38). The relationship between the presence
of DM and Gal-3 levels was further investigated in a
multivariable model adjusting for age, eGFR, AF, and
NYHA functional class, being confounders associated
with Gal-3 at the P < 0.1 level. In this model DM was
independently associated with elevated Gal-3 (β = 0.17,
P = 0.02). An impact of glucose metabolism on Gal-3
levels was further observed by a positive association with
HbA1c (β = 0.25, P = 0.02) (Fig. 2), and FPG (P = 0.02),
but only borderline significantly associated with 2hPG
and HOMA (Table 2). HbA1c was entered in a multivar-
iable model, and demonstrated to have an independent
relation with increasing Gal-3 levels (β = 0.16, P = 0.02).
After full adjustment, no association between Gal-3 and
FPG (P = 0.56, data not shown) was observed.
There was only a trend towards increased plasma
fibulin-1 levels when comparing in HF patients with DM
vs non DM (P = 0.07), although impaired glucose
metabolism assessed by presence of IGT and DM were
associated with equivalent elevated mean fibulin-1 levels
61 ± 16 μg/mL vs. 60 ± 19 μg/mL, respectively compared
to HF patients with NGT 52 ± 13 μg/mL (P = 0.01). Fur-
ther, HbA1c was associated with increasing fibulin-1
Table 1 Baseline characteristics according to diabetes status
Demographics DM (n = 60) Non-DM (n = 95) P value
Age, years 70.8 (9.6) 69.7 (10.8) 0.54
Sex (female/male), % 32/68 33/67 0.90
IHD, n (%) 40 (67) 52 (55) 0.20
NYHA I + II vs. III + IV, % 77/23 85/15 0.21
AF, n (%) 18 (30) 21 (22) 0.30
Systolic BP, mmHg 134 (110–151) 135 (120–146) 0.58
Heart rate, beats/min 73 (66–81) 69 (60–81) 0.03
Metabolism
BMI, kg/m2 28.1 (5.4) 26.3 (5.0) 0.05
FPG, mmol/L 6.9 (1.4) 5.7 (0.5) <0.001
2hPG (mmol/l) 11.7 (2.9) 6.6 (1.9) <0.001
HbA1C, mmol/mol 49 (12) 40 (4) <0.001
HOMA-IR 2.8 (1.5–5.8) 1.7 (1.0–2,8) <0.001
Total cholesterol, mmol/L 4.0 (1.0) 4.4 (1.1) 0.02
Estimated GFR, ml/min/1.73 m2 68 (26) 74 (19) 0.10
Biomarkers
NT-proBNP, pg/mL 1111 (418–2227) 771 (310–1854) 0.08
Gal-3, ng/ml 17.9 (12.9–26.1) 15.6 (12.6–19.3) 0.02
Fibulin-1, μg/ml 60 (19) 55 (13) 0.07
Echocardiographic variables
LVEF rest, % 34 (29–41) 39 (33–45) 0.003
S’ (rest), cm/s 5.2 (4.5–6.5) 5.7 (4.8–6.4) 0.10
E, cm/s 81.6 (62.2–99.7) 72.9 (60.0–92.4) 0.31
e’, cm/s 5.9 (4.6–7.5) 6.6 (5.5–8.7) 0.03
E/e’ (rest) per unit 12.2 (9.6–16.5) 10.2 (8.1–15.4) 0.007
LVEF stress, % 40 (34–47) 49 (40–57) <0.001
LV contractile reserve, % 7 (2–10) 10 (4–15) 0.01
S’ (stress), cm/s 8.3 (6.3–9.6) 7.3 (5.7–8.5) 0.03
Medical treatment
ACE/AngII-inhibitors, n, (%) 85 (89) 48 (80) 0.10
β-blocker, n (%) 53 (88) 72 (76) 0.05
Loop diuretic dose, mg/24 h 60 (0–80) 0 (0–60) 0.001
Oral glucose tolerance test was only performed in the non-diabetic HF patient.
2hPG: 2 h plasma glucose. AF Atrial fibrillation; BMI Body mass index; BSA Body
surface area E Peak early diastolic transmitral flow velocity; e’; early diastolic
longitudinal tissue velocities; FPG Fasting plasma glucose; Gal-3 Galectin-3; GFR
Glomerular filtration rate; HOMA-IR Homeostatic model assessment of Insulin
Resistance. IHD Ischemic heart disease; LV left ventricular; LVEF Left ventricular
ejection fraction; NT-proBNP N-terminal pro B-natriuretic peptide; NYHA NYHA
functional class; S’ Systolic longitudinal tissue velocity
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concentrations (β = 0.21, P = 0.009) (Fig. 2), and this rela-
tion was not markedly attenuated after adjustment for
the confounders age, AF, and eGFR (β = 0.15, P = 0.05).
Fibulin-1 levels which were more than 2SD from mean
Finulin-1 levels were considered outliers. Hence, we ex-
cluded 3 measurements of Fibulin-1 levels which were
considered outliers. The exclusion of the outliers did not
change the results (data not shown).
Galectin-3, fibulin-1 and relationship with LV function
The univariable associations between plasma Gal-3





Fig. 1 Histograms of Galectin-3 and Fibulin-1
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obtained at rest and during LDDE are displayed in Table 3.
There was an association between Gal-3 and LV con-
tractile reserve (β = −0.19, P = 0.03) and Gal-3 and
LVEF during stress (β = −0.25, P = 0.003). In a multi-
variable regression model the association with LV con-
tractile reserve was no longer significant (P = 0.66), as only
DM (β = −0.20, P = 0.03) and eGFR (β = −0.18, P = 0.04)
remained predictive of LV contractile reserve after
complete adjustment (data not shown).
Finally, the patients were divided into two groups; nor-
mal and low eGFR (<60 mL/min/1.73 m2). In both
groups, no association between Gal-3 and LV contractile
reserve (β = −0.06, P = 0.57 in patients with normal
eGFR vs. β = −0.02, P = 0.95 in patients with low eGFR)
was demonstrated. With regard to fibulin-1, resting
LVEF, LVEF and S’ during stress were all associated with
increasing levels of this biomarker in a univariable ana-
lysis, as presented in Table 3. Yet, after adjustment for
relevant co-variables including eGFR no independent as-
sociations between fibulin-1 and these LV systolic mea-
sures were found. An independent relation of fibulin-1
with decreasing eGFR (β = −0.24, P = 0.004) and with
age (β = 0.22, P = 0.008) was observed. Again, the pa-
tients were divided into two groups; normal and low
eGFR (<60 mL/min/1.73 m2). In both groups, no as-
sociation between fibulin-1 and LV contractile reserve
(β = 0.06, P = 0.55 in patients with normal eGFR vs. β =
0.02, P = 0.89 in patients with low eGFR) was presented.
We have performed analyses where the patients with
known diabetes were separated from the patients with
newly diagnosed diabetes. This, however, did not influence
the results.
Discussion
The primary findings of the present study were that
plasma Gal-3 and fibulin-1 levels were elevated in HFrEF
patients with abnormal glucose metabolism compared to
HFrEF patients with NGT. The impact of impaired glu-
cose metabolism on both Gal-3 and fibulin-1 levels was
underlined by an independent association with increas-
ing HbA1c. However, increased Gal-3 and fibulin-1
levels were not associated with the reduced contractile
reserve observed among diabetic HFrEF patients.
Median Gal-3 level was 16.0 ng/mL, which is similar to
findings in comparable HFrEF populations and clearly in-
creased compared to healthy subjects [17, 18]. The mean
fibulin-1 level in our HF population was 57 ± 16 μg/mL,
which is slightly higher than the mean level observed in a
DM population (46 ± 1.3 μg/mL [19]). Fibulin-1 is a novel
biomarker and high concentrations have primarily been
reported in patients with aortic stenosis and DM com-
pared to a level of 5.6 (4.1–8.4) μg/mL reported in healthy
men [11, 20, 21].
The current results suggest that glucose metabolism is
associated with circulating Gal-3 concentrations in HF,
as elevated levels were found in patients with DM and
an association with increasing HbA1c was demonstrated.
The observations were supported by two previous
Table 2 Associations of galectin-3 and fibulin-1 levels with clinical and glucometabolic parameters
Galectin-3 Fibulin-1
Parameter β (SE) P-Value β (SE) P-Value
Age, per year 0.16 (0.23) 0.05 0.36 (0.12) <0.001
Sex 0.04 (0.07) 0.59 −0.09 (2.75) 0.29
Ischemic heart disease −0.01 (0.07) 0.90 −0.009 (2.71) 0.92
NYHA I + II vs. III + IV 0.16 (0.09) 0.06 0.08 (3.37) 0.34
Atrial fibrillation 0.17 (0.07) 0.03 0.17 (2.83) 0.03
Diabetes mellitus 0.27 (0.07) 0.001 0.16 (2.62) 0.05
eGFR, per ml/min/1.73 m2 −0.49 (0.10) <0.001 −0.33 (0.06) <0.001
Metabolism
BMI, per kg/m2 −0.04 (0.006) 0.63 −0.12 (0.25) 0.14
FPG, per mmol/L 0.19 (0.02) 0.02 −0.07 (1.37) 0.44
2hPG, per mmol/L 0.15 (0.01) 0.09 0.26 (0.42) 0.004
HbA1C, per mmol/mol 0.25 (0.16) 0.02 0.21 (0.14) 0.009
HOMA-IR, per unit 0.17 (0.01) 0.06 −0.08 (0.52) 0.36
Biomarkers
NT-proBNP per pg/mL 0.30 (0.12) <0.001 0.38 (2.24) <0.001
Univariable regression models
2hPG 2 h plasma glucose, BMI Body mass index, FPG Fasting plasma glucose, GFR Glomerular filtration rate, HOMA-IR Homeostatic model assessment of insulin
resistance, NT-proBNP N-terminal pro B-natriuretic peptide, NYHA NYHA functional class
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studies reporting increased concentrations in patients
with type 2 DM [18, 21]. However, we found a signifi-
cant impact of renal function on plasma Gal-3 levels
suggesting that other parameters, such as DM complica-
tions like diabetic nephropathy were more predictive of
Gal-3 levels in HFrEF patients.
With regard to fibulin-1 we found elevated concentra-
tions among patients with IGT and DM compared to
NGT and a positive association with HbA1c, which cor-
responds with previous findings among type 2 DM
reporting elevated circulating levels and of an up-
regulation of fibulin-1 in the arterial walls [19, 22].
To our knowledge, the present study is the first to
evaluate the relation between circulating Gal-3 and
fibulin-1 levels and cardiac function evaluated by LDDE.
Galectin-3 was not associated with LV contractile re-
serve and LVEF during low dose dobutamine infusion
after adjusting for relevant confounders, especially eGFR.
The present study demonstrated that impaired renal
function was a strong and independent predictor of
Fig. 2 Scatter plot of HbA1c, Galectin-3 and fibulin-1 levels
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elevated Gal-3 levels, which is in line with previous
studies in patients with DM and in a community cohort
[8, 23]. The elimination of Gal-3 has to our best know-
ledge not been described, but the present findings
indicate a renal component. The gold standard for evalu-
ation of myocardial fibrosis requires an endomyocardial
biopsy, which is a high-risk procedure. Cardiac magnetic
resonance imaging (CMR) is another method that seems
to provide a good estimate of myocardial fibrosis [24, 25].
However, it is technically difficult to perform CMR in pa-
tients with AF and devices; which are highly prevalent in
HFrEF patients. Furthermore, the association between car-
diac fibrosis estimated by CMR and Gal-3 levels is not
well described. In patients with previous myocardial in-
farction Gal-3 was moderately associated with LVEF and
infarct size [26]. We report no association of the bio-
markers Gal-3 with IHD. A proposed mechanism could
be that former MI in our HFrEF patients are not associ-
ated with persisting increased activity of the fibrotic tissue
and thereby secretion to the circulation of these
biomarkers.
Myocardial fibrosis evaluated by histomorphometry
and LV contractile reserve seems associated in patients
with dilated cardiomyopathy [5]. In patients with acute
decompensated HF, the PRIDE study reported a relation-
ship between Gal-3 and resting echocardiographic pa-
rameters related to diastolic function [27]. In the current
cohort of patients with chronic HFrEF we found no in-
dependent association with parameters related to dia-
stolic function (data not shown).
We found no association between fibulin-1 levels and
LV contractile reserve, while univariable associations
were demonstrated between fibulin-1 and resting param-
eters LVEF and S’. However, no association was shown
in the multivariable analyses. This is partly in accord-
ance with data from patients with aorta stenosis, where
fibulin-1 levels were related with S’, but not with LVEF
[10]. Furthermore, we demonstrated a moderate, inverse
association with eGFR which could blunt a potential
weaker association with LV contractile reserve.
Limitations
This is a cross-sectional study. Hence, conclusion re-
garding causality is not possible. A larger sample size
would have allowed us to investigate the IGT group in
more detail.
Conclusion
Galectin-3, but not fibulin-1 levels are elevated in dia-
betic compared to non-diabetic HFrEF patients. Both
Gal-3 and fibulin-1 levels are independently and posi-
tively associated with HbA1c, but not with LV contract-
ile reserve in HF patients.
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